Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication ...

Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...

Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...

Bio-Rad (CA, USA), a clinical diagnostics products company, has launched a new ddPCR kit designed to assess AAV vector quality for gene therapy development. Vericheck ddPCR Empty-Full Capsid Kit can ...

Biogazelle has announced that it is serving a reference laboratory for Bio-Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for ...

In recent years, liquid biopsy approaches have emerged as powerful tools in oncology, enabling non‑invasive, real‑time insights into tumor dynamics. Among these technologies, droplet digital PCR ...

Recent advancements in liquid biopsies have demonstrated the potential of cfDNA as a universal, minimally invasive sample type in cancer prognosis, diagnosis, and prenatal testing 1. In parallel, the ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Bio-Rad Laboratories, Inc. stands tenth on our list and is currently making waves for launching a new ...

Droplet digital polymerase chain reaction (ddPCR) technology is emerging as an efficient, accurate, and precise way to measure transgene copy numbers. With it, scientists may screen for clonal ...